aluates Reports

$ 0.0

Automative

Global Antibody Drug Conjugate CDMO Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-36B16820

Global Antibody Drug Conjugate CDMO Market Research Report 2024

BUY CHAPTERS

Global Antibody Drug Conjugate CDMO Market Research Report 2025

Code: QYRE-Auto-36B16820

Report

July 2025

Pages:100

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Lonza Group

Ajinomoto Bio-Pharma Services

BSP Pharmaceuticals

Porton Pharma Solutions

WuXi XDC

Boc Sciences

Asymchem

Catalent Biologics

3PBIOVIAN

GenScript

AGC Biologics

MabPlex

Chemexpress

Abzena

AbbVie Contract Manufacturing

TOT BIOPHARM

Huadong Medicine

Innovent Biologics

Zhenhao Biology

Antibody Drug Conjugate CDMO Market Size

The global market for Antibody Drug Conjugate CDMO was valued at US$ 3059 million in the year 2024 and is projected to reach a revised size of US$ 7331 million by 2031, growing at a CAGR of 12.7% during the forecast period.

Antibody Drug Conjugate CDMO Market

Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers.A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.

Antibody Drug Conjugates (ADCs) represent one of the fastest-growing and most sophisticated segments in targeted cancer therapy. By combining the precise targeting ability of monoclonal antibodies with the potent cell-killing effect of cytotoxic drugs, ADCs offer a powerful treatment strategy that minimizes harm to healthy tissues.

However, ADCs are among the most complex biologic-drug hybrids to manufacture — they require expertise in biologics production, high-potency active pharmaceutical ingredient (HPAPI) synthesis, advanced conjugation technology, and high-containment fill-finish capabilities.

This is where Contract Development and Manufacturing Organizations (CDMOs) come in. They provide specialized technical infrastructure and know-how for biopharma companies that want to develop and commercialize ADCs without building expensive in-house capacity.

The ADC CDMO market has grown significantly in recent years, fueled by an expanding pipeline of ADCs in clinical trials and rising numbers of commercial approvals. Leading CDMOs now offer end-to-end solutions covering monoclonal antibody production, payload synthesis, conjugation, and sterile, high-containment packaging.

Growing Number of Approved ADCs and Robust Clinical Pipeline

More than a dozen ADCs have received regulatory approval worldwide, with blockbusters like Enhertu®, Padcev®, and Polivy® demonstrating strong commercial success. At the same time, hundreds of new ADCs are in preclinical and clinical development targeting a wide range of cancers and even some non-oncology indications. This expanding pipeline fuels sustained demand for expert CDMO services from early development through to commercial scale-up.

Rising Demand for End-to-End Solutions

Pharma companies increasingly prefer one-stop CDMO partners that can handle the entire ADC value chain — from cell line development to final fill-finish — under a single quality system and contract. This integrated model simplifies supply chains, shortens development timelines, and reduces risk, giving CDMOs with full-spectrum ADC capabilities a competitive edge.

Increased Investment in High-Potency Manufacturing Capacity

As the ADC market expands, leading CDMOs are investing heavily to expand or build new high-containment suites and HPAPI production lines. This growth is critical because HPAPI synthesis and handling require specialized equipment, isolated work areas, and rigorous operator safety systems.

Companies like Lonza, WuXi XDC, Piramal Pharma Solutions, and Sterling Pharma Solutions have made significant capital investments to meet the increasing global demand.

This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate CDMO.

The Antibody Drug Conjugate CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody Drug Conjugate CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antibody Drug Conjugate CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Antibody Drug Conjugate CDMO Market Report

Report Metric	Details
Report Name	Antibody Drug Conjugate CDMO Market
Accounted market size in year	US$ 3059 million
Forecasted market size in 2031	US$ 7331 million
CAGR	12.7%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Cleavable Linker ADCs Non-Cleavable Linker ADCs
Segment by Application	Small and Medium-sized Pharmaceutical Companies Large Pharmaceutical Companies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza Group, Porton Pharma Solutions, WuXi XDC, BOC Sciences, Asymchem, Catalent Biologics, 3PBIOVIAN, Genscript, AGC Biologics, MabPlex, ChemExpress, Abzena, Ajinomoto Bio-Pharma Services, BSP Pharmaceuticals, AbbVie Contract Manufacturing, TOT Biopharm, Huadong Medicine, Innovent Biologics, Zhenhao Biology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Antibody Drug Conjugate CDMO Market growing?

Ans: The Antibody Drug Conjugate CDMO Market witnessing a CAGR of 12.7% during the forecast period 2025-2031.

What is the Antibody Drug Conjugate CDMO Market size in 2031?

Ans: The Antibody Drug Conjugate CDMO Market size in 2031 will be US$ 7331 million.

Who are the main players in the Antibody Drug Conjugate CDMO Market report?

Ans: The main players in the Antibody Drug Conjugate CDMO Market are Lonza Group, Porton Pharma Solutions, WuXi XDC, BOC Sciences, Asymchem, Catalent Biologics, 3PBIOVIAN, Genscript, AGC Biologics, MabPlex, ChemExpress, Abzena, Ajinomoto Bio-Pharma Services, BSP Pharmaceuticals, AbbVie Contract Manufacturing, TOT Biopharm, Huadong Medicine, Innovent Biologics, Zhenhao Biology

What are the Application segmentation covered in the Antibody Drug Conjugate CDMO Market report?

Ans: The Applications covered in the Antibody Drug Conjugate CDMO Market report are Small and Medium-sized Pharmaceutical Companies, Large Pharmaceutical Companies

What are the Type segmentation covered in the Antibody Drug Conjugate CDMO Market report?

Ans: The Types covered in the Antibody Drug Conjugate CDMO Market report are Cleavable Linker ADCs, Non-Cleavable Linker ADCs

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Cleavable Linker ADCs

1.2.3 Non-Cleavable Linker ADCs

1.3 Market by Application

1.3.1 Global Antibody Drug Conjugate CDMO Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Small and Medium-sized Pharmaceutical Companies

1.3.3 Large Pharmaceutical Companies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Antibody Drug Conjugate CDMO Market Perspective (2020-2031)

2.2 Global Antibody Drug Conjugate CDMO Growth Trends by Region

2.2.1 Global Antibody Drug Conjugate CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Antibody Drug Conjugate CDMO Historic Market Size by Region (2020-2025)

2.2.3 Antibody Drug Conjugate CDMO Forecasted Market Size by Region (2026-2031)

2.3 Antibody Drug Conjugate CDMO Market Dynamics

2.3.1 Antibody Drug Conjugate CDMO Industry Trends

2.3.2 Antibody Drug Conjugate CDMO Market Drivers

2.3.3 Antibody Drug Conjugate CDMO Market Challenges

2.3.4 Antibody Drug Conjugate CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue

3.1.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue (2020-2025)

3.1.2 Global Antibody Drug Conjugate CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Top Antibody Drug Conjugate CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Antibody Drug Conjugate CDMO Revenue

3.4 Global Antibody Drug Conjugate CDMO Market Concentration Ratio

3.4.1 Global Antibody Drug Conjugate CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate CDMO Revenue in 2024

3.5 Global Key Players of Antibody Drug Conjugate CDMO Head office and Area Served

3.6 Global Key Players of Antibody Drug Conjugate CDMO, Product and Application

3.7 Global Key Players of Antibody Drug Conjugate CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody Drug Conjugate CDMO Breakdown Data by Type

4.1 Global Antibody Drug Conjugate CDMO Historic Market Size by Type (2020-2025)

4.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2026-2031)

5 Antibody Drug Conjugate CDMO Breakdown Data by Application

5.1 Global Antibody Drug Conjugate CDMO Historic Market Size by Application (2020-2025)

5.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Antibody Drug Conjugate CDMO Market Size (2020-2031)

6.2 North America Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)

6.4 North America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Antibody Drug Conjugate CDMO Market Size (2020-2031)

7.2 Europe Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)

7.4 Europe Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Antibody Drug Conjugate CDMO Market Size (2020-2031)

8.2 Asia-Pacific Antibody Drug Conjugate CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Antibody Drug Conjugate CDMO Market Size (2020-2031)

9.2 Latin America Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)

9.4 Latin America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Antibody Drug Conjugate CDMO Market Size (2020-2031)

10.2 Middle East & Africa Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza Group

11.1.1 Lonza Group Company Details

11.1.2 Lonza Group Business Overview

11.1.3 Lonza Group Antibody Drug Conjugate CDMO Introduction

11.1.4 Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.1.5 Lonza Group Recent Development

11.2 Porton Pharma Solutions

11.2.1 Porton Pharma Solutions Company Details

11.2.2 Porton Pharma Solutions Business Overview

11.2.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Introduction

11.2.4 Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.2.5 Porton Pharma Solutions Recent Development

11.3 WuXi XDC

11.3.1 WuXi XDC Company Details

11.3.2 WuXi XDC Business Overview

11.3.3 WuXi XDC Antibody Drug Conjugate CDMO Introduction

11.3.4 WuXi XDC Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.3.5 WuXi XDC Recent Development

11.4 BOC Sciences

11.4.1 BOC Sciences Company Details

11.4.2 BOC Sciences Business Overview

11.4.3 BOC Sciences Antibody Drug Conjugate CDMO Introduction

11.4.4 BOC Sciences Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.4.5 BOC Sciences Recent Development

11.5 Asymchem

11.5.1 Asymchem Company Details

11.5.2 Asymchem Business Overview

11.5.3 Asymchem Antibody Drug Conjugate CDMO Introduction

11.5.4 Asymchem Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.5.5 Asymchem Recent Development

11.6 Catalent Biologics

11.6.1 Catalent Biologics Company Details

11.6.2 Catalent Biologics Business Overview

11.6.3 Catalent Biologics Antibody Drug Conjugate CDMO Introduction

11.6.4 Catalent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.6.5 Catalent Biologics Recent Development

11.7 3PBIOVIAN

11.7.1 3PBIOVIAN Company Details

11.7.2 3PBIOVIAN Business Overview

11.7.3 3PBIOVIAN Antibody Drug Conjugate CDMO Introduction

11.7.4 3PBIOVIAN Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.7.5 3PBIOVIAN Recent Development

11.8 Genscript

11.8.1 Genscript Company Details

11.8.2 Genscript Business Overview

11.8.3 Genscript Antibody Drug Conjugate CDMO Introduction

11.8.4 Genscript Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.8.5 Genscript Recent Development

11.9 AGC Biologics

11.9.1 AGC Biologics Company Details

11.9.2 AGC Biologics Business Overview

11.9.3 AGC Biologics Antibody Drug Conjugate CDMO Introduction

11.9.4 AGC Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.9.5 AGC Biologics Recent Development

11.10 MabPlex

11.10.1 MabPlex Company Details

11.10.2 MabPlex Business Overview

11.10.3 MabPlex Antibody Drug Conjugate CDMO Introduction

11.10.4 MabPlex Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.10.5 MabPlex Recent Development

11.11 ChemExpress

11.11.1 ChemExpress Company Details

11.11.2 ChemExpress Business Overview

11.11.3 ChemExpress Antibody Drug Conjugate CDMO Introduction

11.11.4 ChemExpress Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.11.5 ChemExpress Recent Development

11.12 Abzena

11.12.1 Abzena Company Details

11.12.2 Abzena Business Overview

11.12.3 Abzena Antibody Drug Conjugate CDMO Introduction

11.12.4 Abzena Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.12.5 Abzena Recent Development

11.13 Ajinomoto Bio-Pharma Services

11.13.1 Ajinomoto Bio-Pharma Services Company Details

11.13.2 Ajinomoto Bio-Pharma Services Business Overview

11.13.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Introduction

11.13.4 Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.13.5 Ajinomoto Bio-Pharma Services Recent Development

11.14 BSP Pharmaceuticals

11.14.1 BSP Pharmaceuticals Company Details

11.14.2 BSP Pharmaceuticals Business Overview

11.14.3 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Introduction

11.14.4 BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.14.5 BSP Pharmaceuticals Recent Development

11.15 AbbVie Contract Manufacturing

11.15.1 AbbVie Contract Manufacturing Company Details

11.15.2 AbbVie Contract Manufacturing Business Overview

11.15.3 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Introduction

11.15.4 AbbVie Contract Manufacturing Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.15.5 AbbVie Contract Manufacturing Recent Development

11.16 TOT Biopharm

11.16.1 TOT Biopharm Company Details

11.16.2 TOT Biopharm Business Overview

11.16.3 TOT Biopharm Antibody Drug Conjugate CDMO Introduction

11.16.4 TOT Biopharm Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.16.5 TOT Biopharm Recent Development

11.17 Huadong Medicine

11.17.1 Huadong Medicine Company Details

11.17.2 Huadong Medicine Business Overview

11.17.3 Huadong Medicine Antibody Drug Conjugate CDMO Introduction

11.17.4 Huadong Medicine Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.17.5 Huadong Medicine Recent Development

11.18 Innovent Biologics

11.18.1 Innovent Biologics Company Details

11.18.2 Innovent Biologics Business Overview

11.18.3 Innovent Biologics Antibody Drug Conjugate CDMO Introduction

11.18.4 Innovent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.18.5 Innovent Biologics Recent Development

11.19 Zhenhao Biology

11.19.1 Zhenhao Biology Company Details

11.19.2 Zhenhao Biology Business Overview

11.19.3 Zhenhao Biology Antibody Drug Conjugate CDMO Introduction

11.19.4 Zhenhao Biology Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.19.5 Zhenhao Biology Recent Development

11.20 Porton Pharma Solutions

11.20.1 Porton Pharma Solutions Company Details

11.20.2 Porton Pharma Solutions Business Overview

11.20.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Introduction

11.20.4 Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.20.5 Porton Pharma Solutions Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Lonza Group

Ajinomoto Bio-Pharma Services

BSP Pharmaceuticals

Porton Pharma Solutions

WuXi XDC

Boc Sciences

Asymchem

Catalent Biologics

3PBIOVIAN

GenScript

AGC Biologics

MabPlex

Chemexpress

Abzena

AbbVie Contract Manufacturing

TOT BIOPHARM

Huadong Medicine

Innovent Biologics

Zhenhao Biology

List of Tables

Table 1. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Cleavable Linker ADCs

Table 3. Key Players of Non-Cleavable Linker ADCs

Table 4. Global Antibody Drug Conjugate CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Antibody Drug Conjugate CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Antibody Drug Conjugate CDMO Market Share by Region (2020-2025)

Table 8. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Antibody Drug Conjugate CDMO Market Share by Region (2026-2031)

Table 10. Antibody Drug Conjugate CDMO Market Trends

Table 11. Antibody Drug Conjugate CDMO Market Drivers

Table 12. Antibody Drug Conjugate CDMO Market Challenges

Table 13. Antibody Drug Conjugate CDMO Market Restraints

Table 14. Global Antibody Drug Conjugate CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Antibody Drug Conjugate CDMO Market Share by Players (2020-2025)

Table 16. Global Top Antibody Drug Conjugate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2024)

Table 17. Ranking of Global Top Antibody Drug Conjugate CDMO Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Antibody Drug Conjugate CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Antibody Drug Conjugate CDMO, Headquarters and Area Served

Table 20. Global Key Players of Antibody Drug Conjugate CDMO, Product and Application

Table 21. Global Key Players of Antibody Drug Conjugate CDMO, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Antibody Drug Conjugate CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2020-2025)

Table 25. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2026-2031)

Table 27. Global Antibody Drug Conjugate CDMO Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2020-2025)

Table 29. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2026-2031)

Table 31. North America Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Antibody Drug Conjugate CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 46. Lonza Group Company Details

Table 47. Lonza Group Business Overview

Table 48. Lonza Group Antibody Drug Conjugate CDMO Product

Table 49. Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 50. Lonza Group Recent Development

Table 51. Porton Pharma Solutions Company Details

Table 52. Porton Pharma Solutions Business Overview

Table 53. Porton Pharma Solutions Antibody Drug Conjugate CDMO Product

Table 54. Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 55. Porton Pharma Solutions Recent Development

Table 56. WuXi XDC Company Details

Table 57. WuXi XDC Business Overview

Table 58. WuXi XDC Antibody Drug Conjugate CDMO Product

Table 59. WuXi XDC Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 60. WuXi XDC Recent Development

Table 61. BOC Sciences Company Details

Table 62. BOC Sciences Business Overview

Table 63. BOC Sciences Antibody Drug Conjugate CDMO Product

Table 64. BOC Sciences Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 65. BOC Sciences Recent Development

Table 66. Asymchem Company Details

Table 67. Asymchem Business Overview

Table 68. Asymchem Antibody Drug Conjugate CDMO Product

Table 69. Asymchem Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 70. Asymchem Recent Development

Table 71. Catalent Biologics Company Details

Table 72. Catalent Biologics Business Overview

Table 73. Catalent Biologics Antibody Drug Conjugate CDMO Product

Table 74. Catalent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 75. Catalent Biologics Recent Development

Table 76. 3PBIOVIAN Company Details

Table 77. 3PBIOVIAN Business Overview

Table 78. 3PBIOVIAN Antibody Drug Conjugate CDMO Product

Table 79. 3PBIOVIAN Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 80. 3PBIOVIAN Recent Development

Table 81. Genscript Company Details

Table 82. Genscript Business Overview

Table 83. Genscript Antibody Drug Conjugate CDMO Product

Table 84. Genscript Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 85. Genscript Recent Development

Table 86. AGC Biologics Company Details

Table 87. AGC Biologics Business Overview

Table 88. AGC Biologics Antibody Drug Conjugate CDMO Product

Table 89. AGC Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 90. AGC Biologics Recent Development

Table 91. MabPlex Company Details

Table 92. MabPlex Business Overview

Table 93. MabPlex Antibody Drug Conjugate CDMO Product

Table 94. MabPlex Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 95. MabPlex Recent Development

Table 96. ChemExpress Company Details

Table 97. ChemExpress Business Overview

Table 98. ChemExpress Antibody Drug Conjugate CDMO Product

Table 99. ChemExpress Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 100. ChemExpress Recent Development

Table 101. Abzena Company Details

Table 102. Abzena Business Overview

Table 103. Abzena Antibody Drug Conjugate CDMO Product

Table 104. Abzena Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 105. Abzena Recent Development

Table 106. Ajinomoto Bio-Pharma Services Company Details

Table 107. Ajinomoto Bio-Pharma Services Business Overview

Table 108. Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product

Table 109. Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 110. Ajinomoto Bio-Pharma Services Recent Development

Table 111. BSP Pharmaceuticals Company Details

Table 112. BSP Pharmaceuticals Business Overview

Table 113. BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product

Table 114. BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 115. BSP Pharmaceuticals Recent Development

Table 116. AbbVie Contract Manufacturing Company Details

Table 117. AbbVie Contract Manufacturing Business Overview

Table 118. AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Product

Table 119. AbbVie Contract Manufacturing Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 120. AbbVie Contract Manufacturing Recent Development

Table 121. TOT Biopharm Company Details

Table 122. TOT Biopharm Business Overview

Table 123. TOT Biopharm Antibody Drug Conjugate CDMO Product

Table 124. TOT Biopharm Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 125. TOT Biopharm Recent Development

Table 126. Huadong Medicine Company Details

Table 127. Huadong Medicine Business Overview

Table 128. Huadong Medicine Antibody Drug Conjugate CDMO Product

Table 129. Huadong Medicine Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 130. Huadong Medicine Recent Development

Table 131. Innovent Biologics Company Details

Table 132. Innovent Biologics Business Overview

Table 133. Innovent Biologics Antibody Drug Conjugate CDMO Product

Table 134. Innovent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 135. Innovent Biologics Recent Development

Table 136. Zhenhao Biology Company Details

Table 137. Zhenhao Biology Business Overview

Table 138. Zhenhao Biology Antibody Drug Conjugate CDMO Product

Table 139. Zhenhao Biology Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 140. Zhenhao Biology Recent Development

Table 141. Porton Pharma Solutions Company Details

Table 142. Porton Pharma Solutions Business Overview

Table 143. Porton Pharma Solutions Antibody Drug Conjugate CDMO Product

Table 144. Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 145. Porton Pharma Solutions Recent Development

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources

Table 149. Authors List of This Report

List of Figures

Figure 1. Antibody Drug Conjugate CDMO Picture

Figure 2. Global Antibody Drug Conjugate CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Antibody Drug Conjugate CDMO Market Share by Type: 2024 VS 2031

Figure 4. Cleavable Linker ADCs Features

Figure 5. Non-Cleavable Linker ADCs Features

Figure 6. Global Antibody Drug Conjugate CDMO Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Antibody Drug Conjugate CDMO Market Share by Application: 2024 VS 2031

Figure 8. Small and Medium-sized Pharmaceutical Companies Case Studies

Figure 9. Large Pharmaceutical Companies Case Studies

Figure 10. Antibody Drug Conjugate CDMO Report Years Considered

Figure 11. Global Antibody Drug Conjugate CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Antibody Drug Conjugate CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Antibody Drug Conjugate CDMO Market Share by Region: 2024 VS 2031

Figure 14. Global Antibody Drug Conjugate CDMO Market Share by Players in 2024

Figure 15. Global Antibody Drug Conjugate CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 16. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate CDMO Revenue in 2024

Figure 17. North America Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 18. North America Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)

Figure 19. United States Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. Canada Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Europe Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)

Figure 23. Germany Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. France Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. U.K. Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Italy Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Russia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Ireland Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Asia-Pacific Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Region (2020-2031)

Figure 31. China Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Japan Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. South Korea Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Southeast Asia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. India Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Australia & New Zealand Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Latin America Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)

Figure 39. Mexico Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Brazil Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Middle East & Africa Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)

Figure 43. Israel Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Saudi Arabia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. UAE Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Lonza Group Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 47. Porton Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 48. WuXi XDC Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 49. BOC Sciences Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 50. Asymchem Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 51. Catalent Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 52. 3PBIOVIAN Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 53. Genscript Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 54. AGC Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 55. MabPlex Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 56. ChemExpress Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 57. Abzena Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 58. Ajinomoto Bio-Pharma Services Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 59. BSP Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 60. AbbVie Contract Manufacturing Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 61. TOT Biopharm Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 62. Huadong Medicine Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 63. Innovent Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 64. Zhenhao Biology Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 65. Porton Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Antibody drug Conjugate for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antibody drug Conjugates Market Insights Forecast to 2030

Global ADC Drug CDMO Service Market Research Report 2024

Global Antibody drug Conjugates for Tumors Market Research Report 2024

Global HER2 Antibody Drug Conjugate Market Research Report 2025

Global Antibody drug Conjugate ADC Payload Market Research Report 2025

Global Monoclonal Antibody ADC Drugs Market Research Report 2025

Global Antibody Drug Conjugates Contract Manufacturing Market Research Report 2025

Global ADC Linkers Market Research Report 2024

Antibody Drug Conjugate ADC Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide Drug Conjugates PDCs CDMO Service Market Research Report 2024

Global Antibody Oligonucleotide Conjugates AOC Drug CDMO Market Research Report 2024

Global ADC Manufacturing Service Market Research Report 2025

Global Highly Potent API HPAPI For Antibody drug Conjugate ADC Market Research Report 2025

Global HER2 ADC Drugs Market Research Report 2024

Global Antibody Drug CDMO Service Market Research Report 2024

Global Antibody radionuclide Conjugates Market Research Report 2024

Global Cancer Antibody Drug Conjugates Market Research Report 2024

Global Conjugated Monoclonal Antibodies Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions